Bring on the heterodox challenges!

For years, amongst my funding colleagues and in scientific settings I have questioned whether we needed a serious re-think about the Alzheimer Disease research dogma. Certain things about the amyloid hypothesis and the clinical disease just do not add up — and to my mind AD has become the classic example of the MODEL of the disease becoming the focus of research, in place of the actual disease. I also have long believed that once a system is tipped too far it can not recover. Recent news about AD drug discover is supporting these contentions. http://www.nytimes.com/2010/08/18/business/18lilly.html
The time has come for philanthropic organizations with an interest in neurological disease to start challenging the status quo.